Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) and Immatics (NASDAQ:IMTX – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
Analyst Ratings
This is a summary of current recommendations and price targets for Akebia Therapeutics and Immatics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Akebia Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Immatics | 1 | 1 | 6 | 0 | 2.62 |
Akebia Therapeutics currently has a consensus target price of $3.90, indicating a potential upside of 331.89%. Immatics has a consensus target price of $20.60, indicating a potential upside of 139.53%. Given Akebia Therapeutics’ higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Immatics.
Institutional & Insider Ownership
Risk and Volatility
Akebia Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Immatics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.
Earnings & Valuation
This table compares Akebia Therapeutics and Immatics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Akebia Therapeutics | $219.06 million | 1.14 | -$5.34 million | ($0.11) | -8.21 |
| Immatics | $54.60 million | 21.53 | -$222.26 million | ($1.86) | -4.62 |
Akebia Therapeutics has higher revenue and earnings than Immatics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Akebia Therapeutics and Immatics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Akebia Therapeutics | -13.54% | -88.88% | -7.74% |
| Immatics | -495.71% | -47.41% | -39.45% |
About Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company’s product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About Immatics
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
